Geron Corporation (NASDAQ:GERN) — Market Cap & Net Worth
Market Cap & Net Worth: Geron Corporation (GERN)
Geron Corporation (NASDAQ:GERN) has a market capitalization of $1.01 Billion ($1.01 Billion) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #9074 globally and #2425 in its home market, demonstrating a 5.33% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Geron Corporation's stock price $1.58 by its total outstanding shares 638355275 (638.36 Million). Analyse Geron Corporation (GERN) cash flow conversion to see how efficiently the company converts income to cash.
Geron Corporation Market Cap History: 2015 to 2026
Geron Corporation's market capitalization history from 2015 to 2026. Data shows change from $3.09 Billion to $1.01 Billion (-6.70% CAGR).
Index Memberships
Geron Corporation is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.04% | #245 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #931 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.67 Trillion | 0.06% | #147 of 263 |
Weight: Geron Corporation's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Geron Corporation Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Geron Corporation's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
29.35x
Geron Corporation's market cap is 29.35 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $3.09 Billion | $36.37 Million | $46.00K | 84.95x | 67166.08x |
| 2016 | $1.32 Billion | $6.16 Million | -$29.54 Million | 214.44x | N/A |
| 2017 | $1.15 Billion | $1.06 Million | -$27.92 Million | 1078.91x | N/A |
| 2018 | $638.36 Million | $1.07 Million | -$27.02 Million | 598.83x | N/A |
| 2019 | $868.16 Million | $460.00K | -$63.55 Million | 1887.31x | N/A |
| 2020 | $1.01 Billion | $253.00K | -$75.62 Million | 4011.80x | N/A |
| 2021 | $778.79 Million | $1.39 Million | -$116.11 Million | 559.08x | N/A |
| 2022 | $1.54 Billion | $596.00K | -$141.90 Million | 2591.98x | N/A |
| 2023 | $1.35 Billion | $237.00K | -$184.13 Million | 5683.25x | N/A |
| 2024 | $2.26 Billion | $76.99 Million | -$174.57 Million | 29.35x | N/A |
Competitor Companies of GERN by Market Capitalization
Companies near Geron Corporation in the global market cap rankings as of May 4, 2026.
Key companies related to Geron Corporation by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Geron Corporation Historical Marketcap From 2015 to 2026
Between 2015 and today, Geron Corporation's market cap moved from $3.09 Billion to $ 1.01 Billion, with a yearly change of -6.70%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.01 Billion | +19.70% |
| 2025 | $842.63 Million | -62.71% |
| 2024 | $2.26 Billion | +67.77% |
| 2023 | $1.35 Billion | -12.81% |
| 2022 | $1.54 Billion | +98.36% |
| 2021 | $778.79 Million | -23.27% |
| 2020 | $1.01 Billion | +16.91% |
| 2019 | $868.16 Million | +36.00% |
| 2018 | $638.36 Million | -44.44% |
| 2017 | $1.15 Billion | -13.04% |
| 2016 | $1.32 Billion | -57.23% |
| 2015 | $3.09 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Geron Corporation was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.01 Billion USD |
| MoneyControl | $1.01 Billion USD |
| MarketWatch | $1.01 Billion USD |
| marketcap.company | $1.01 Billion USD |
| Reuters | $1.01 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Geron Corporation
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California.